Prescient Therapeutics Ltd has released a press release.
US FDA allows PTX-100 Ph2 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- Appointment of Chief Executive Officer
- September 2024 Quarterly Update and Appendix 4C
- Prescient CEO to step down in early 2025
- Appendix 4E and 2024 Annual Report
- June 2024 Quarterly Update and Appendix 4C
Later from Prescient Therapeutics
- December 2024 Quarterly Update and Appendix 4C
- December 2024 Quarterly Update and Appendix 4C - amended
- PTX Opens First Clinical site for PTX-100 Phase 2a Study
- PTX-100 receives U.S. FDA Fast Track Designation
- March 2025 Quarterly Update and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics